Sergei Gryaznov
Directeur Technique/Scientifique/R&D chez MAIA BIOTECHNOLOGY, INC.
Fortune : 119 289 $ au 30/04/2024
Profil
Sergei M.
Gryaznov is the founder of Lynx Therapeutics, Inc. (founded in 1993).
He is currently the Chief Scientific Officer at MAIA Biotechnology, Inc. (since 2019).
Dr. Gryaznov previously worked as the Chemistry Director at Geron Corp.
(from 1998 to 2013) and as the Chief Technology Officer at Exicure Operating Co. Dr. Gryaznov holds graduate and doctorate degrees from Moscow State University Lomonosov.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MAIA BIOTECHNOLOGY, INC.
0,22% | 26/04/2024 | 44 511 ( 0,22% ) | 119 289 $ | 30/04/2024 |
Postes actifs de Sergei Gryaznov
| Sociétés | Poste | Début |
|---|---|---|
| MAIA BIOTECHNOLOGY, INC. | Directeur Technique/Scientifique/R&D | 01/12/2019 |
Anciens postes connus de Sergei Gryaznov
| Sociétés | Poste | Fin |
|---|---|---|
| GERON CORPORATION | Corporate Officer/Principal | 01/01/2013 |
Lynx Therapeutics, Inc.
 Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Lynx Therapeutics, Inc. was a developer of genetic analysis products for the pharmaceutical, biotechnology and agriculture industries. It's MPSSTM instruments analyze millions of DNA molecules in parallel enabling genome structure characterization at an unprecedented level of resolution. MPSSTM provides comprehensive and quantitative digital information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. The company was headquartered in Hayward, CA. | Corporate Officer/Principal | 01/01/1997 |
Exicure Operating Co.
 Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Directeur Technique/Scientifique/R&D | - |
Formation de Sergei Gryaznov
| Moscow State University Lomonosov | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GERON CORPORATION | Health Technology |
| MAIA BIOTECHNOLOGY, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Exicure Operating Co.
Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Health Technology |
Lynx Therapeutics, Inc.
Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Lynx Therapeutics, Inc. was a developer of genetic analysis products for the pharmaceutical, biotechnology and agriculture industries. It's MPSSTM instruments analyze millions of DNA molecules in parallel enabling genome structure characterization at an unprecedented level of resolution. MPSSTM provides comprehensive and quantitative digital information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. The company was headquartered in Hayward, CA. | Health Technology |
